Viatris Inc (VTRS) stock
VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/309% below fair value
$20.45−0.29 (-1.40%)
Close on Nov 17, 2026Market cap $23.49BP/E –Yield 2.35%
Viatris cash
Cash and short-term investments held at the end of each period.
Viatris's cash was $886.50M at Jun 30, 2026. For fiscal 2025 it was $1.36B, up 76.1% from the year before. The highest annual figure on record is $1.36B in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | +76.1% |
| FY2024 | Dec 31, 2024 | $774.10M | -24.8% |
| FY2023 | Dec 31, 2023 | $1.03B | -20.7% |
| FY2022 | Dec 31, 2022 | $1.30B | +74.3% |
| FY2021 | Dec 31, 2021 | $744.40M | -16.3% |
| FY2020 | Dec 31, 2020 | $889.10M | +81.0% |
| FY2019 | Dec 31, 2019 | $491.10M | +26.1% |
| FY2018 | Dec 31, 2018 | $389.30M | +5.2% |
| FY2017 | Dec 31, 2017 | $369.90M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $886.50M | +56.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.80B | +139.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.36B | +76.1% |
| Q3 FY2025 | Sep 30, 2025 | $975.30M | -48.1% |
| Q2 FY2025 | Jun 30, 2025 | $566.40M | -38.2% |
| Q1 FY2025 | Mar 31, 2025 | $755.00M | -25.6% |
| Q4 FY2024 | Dec 31, 2024 | $774.10M | -24.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.88B | +43.5% |
| Q2 FY2024 | Jun 30, 2024 | $917.20M | +45.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.01B | +100.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.03B | -20.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.31B | +102.5% |
| Q2 FY2023 | Jun 30, 2023 | $629.20M | -5.3% |
| Q1 FY2023 | Mar 31, 2023 | $506.60M | -32.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.30B | +74.3% |
| Q3 FY2022 | Sep 30, 2022 | $646.70M | -14.5% |
| Q2 FY2022 | Jun 30, 2022 | $664.70M | -1.4% |
| Q1 FY2022 | Mar 31, 2022 | $752.40M | -6.8% |
| Q4 FY2021 | Dec 31, 2021 | $744.40M | -16.3% |
| Q3 FY2021 | Sep 30, 2021 | $756.60M | +13.9% |
| Q2 FY2021 | Jun 30, 2021 | $673.90M | +108.3% |
| Q1 FY2021 | Mar 31, 2021 | $806.90M | +41.0% |
| Q4 FY2020 | Dec 31, 2020 | $889.10M | +81.0% |
| Q3 FY2020 | Sep 30, 2020 | $664.50M | – |
| Q2 FY2020 | Jun 30, 2020 | $323.60M | – |
| Q1 FY2020 | Mar 31, 2020 | $572.40M | – |
| Q4 FY2019 | Dec 31, 2019 | $491.10M | +26.1% |
| Q3 FY2019 | Sep 29, 2019 | $0 | -100.0% |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $389.30M | – |
| Q4 FY2017 | Dec 31, 2017 | $369.90M | – |
See a number that looks wrong?